[Source: PipelineReview] – InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology.
Scientists at InNexus have designed and produced by recombinant technology, a novel antibody product directed at treatment of psoriasis, an autoimmune skin disease. The product, designated IXSCD11a, is being formulated for topical use either as a lotion or in patches to be applied to affected areas. IXSCD11a is an antibody fragment based on InNexus’ Transmab technology that penetrates cell membranes and dermal barriers. IXSCD11a has shown significant increase in cell penetration compared to other products targeting psoriasis.